Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients
Abroad (travel likely)RecruitingPHASE2
Conditions
Melanoma Stage III · Melanoma Stage IV
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Contact: Study coordinator (Danielle Marie Bello, MD)
Study leads
Danielle Bello
Principal Investigator
Memorial Sloan Kettering Cancer Center